Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | IKBKB | O14920 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112059 | 0.84 | JAK2 (0.44) | KDM4EALDH1A1HPGDIKBKBMAPT | |
| SCHEMBL3124862 | 0.81 | IKBKB (0.71) | KDM4EALDH1A1HPGDIKBKBHSD17B10 | |
| SCHEMBL3127593 | 0.81 | IKBKB (0.67) | KDM4EALDH1A1HPGDIKBKBHSD17B10 | |
| SCHEMBL11622274 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1HPGDIKBKBHSD17B10 | |
| SCHEMBL3124515 | 0.77 | IKBKB (0.65) | KDM4EALDH1A1HPGDIKBKBHSD17B10 | |
| SCHEMBL3759050 | 0.75 | IKBKB (0.74) | KDM4EALDH1A1HPGDIKBKBHSD17B10 | |
| SCHEMBL1683739 | 0.73 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL3129704 | 0.73 | IKBKB (0.72) | KDM4EALDH1A1HPGDIKBKBHSD17B10 | |
| SCHEMBL3123540 | 0.73 | JAK2 (0.45) | ALDH1A1IKBKBMAPTLMNANPC1 | |
| SCHEMBL3127678 | 0.72 | IKBKB (0.66) | KDM4EALDH1A1HPGDIKBKBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170849-B1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LTD (GB) | 2016-12-21 | — | — | EP | claimed |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2015-02-26 | — | — | US | claimed |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2013-04-25 | — | — | US | claimed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | claimed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | claimed |
| CN-101796038-A | Oxazole tyrosine kinase inhibitors | SAREUM LTD | 2010-08-04 | — | — | CN | claimed |
| WO-2010055304-A2 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2010-05-20 | — | — | WO | claimed |
| EP-2170849-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | Sareum Limited (GB) | 2010-04-07 | — | — | EP | claimed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | claimed |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | disclosed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | disclosed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2020-03-19 | — | — | US | disclosed |
| EP-2170849-B1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| CN-101796038-A | Oxazole tyrosine kinase inhibitors | SAREUM LTD | 2010-08-04 | — | — | CN | disclosed |
| WO-2010055304-A2 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2010-05-20 | — | — | WO | disclosed |
| EP-2170849-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | Sareum Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | KDM4E 127/4885ALDH1A1 4014/4885HPGD 4849/4885 |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | KDM4E 127/4885ALDH1A1 4014/4885HPGD 4849/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | KDM4E 127/4885ALDH1A1 4014/4885HPGD 4849/4885 |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | KDM4E 718/4885ALDH1A1 1403/4885HPGD 4701/4885 |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | KDM4E 718/4885ALDH1A1 1403/4885HPGD 4701/4885 |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | KDM4E 675/4885ALDH1A1 1431/4885HPGD 4686/4885 |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | KDM4E 127/4885ALDH1A1 4014/4885HPGD 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.